Latest "CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma" News Stories

12:49 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma" found in our extensive news archives from over 250 global news sources.

More Information about CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma for you to read. Along with our medical data and news we also list CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma Clinical Trials, which are updated daily. BioPortfolio also has a large database of CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma Companies for you to search.

Showing "CDK4 Inhibition Locally Advanced Metastatic Chordoma" News Articles 1–25 of 5,900+

Tuesday 26th March 2019

Progress Continues in HR+/HER2- Breast Cancer Paradigm

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

Spok Improves Care Team Communication at Vail Health

Community health system expands use of Spok Care Connect® across its medical centers and clinics Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a global leader in healthcare communications, announced that Vail Health has improved care team communication with

McKesson ideaShare Unites Independent Pharmacy

Premier community pharmacy education and networking event hits Orlando in 2019 Registration is now open for McKesson ideaShare in Orlando from June 26–30, 2019. Pharmacists, pharmacy owners and pharmacy technicians have the chance to

Catalent Biologics to Present on Tech Transfer, Biomanufacturing and Aseptic Processing at INTERPHEX

Catalent Pharma Solutions (Booth 1145), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that two of its manufacturing experts will present at the INTERPHEX Conference and Exhibition, taking place at the Javits Center, New York City, on April 2-4, 2019. SOMERSET, N.J. (PRWEB) March 26, 2019 C...

Fina Biosolutions’ Licensee Successfully Completes a Phase 3 Study and Enters World Health Organization (WHO) Registration for Pneumosil®

Serum Institute of India completes a Phase 3 clinical trial with chemistry developed by Fina Biosolutions Fina Biosolutions is pleased to announce that the Serum Institute of India Private Limited (SIIPL), has completed a Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which the Serum Institute indicates all primary and sec...

New Claritag Advanced Cryogenics Skincare Solution Introduces At-Home Beauty Options

Innovative device easily removes pesky skin tags; achieve dermatologist-quality results without the cost Claritag™, the leading beauty solution for at-home skin tag removal, has optimized the design of its cryogenics skincare product. Developed by leading dermatologists and skincare professionals, Claritag’s innovative proprietary te

Archway Health Announces Partnership With A-Rated Insurance Carrier on Launch of Value-Based Risk Protection for Providers

New Reinsurance Program Protects Healthcare Providers Participating in Value-Based Payment Programs As healthcare migrates from fee-for-service payment models to value-based care, providers increasingly seek solutions that offer them protection against losses within two-sided, risk-based arrangements. Today, Archway Health, an innovator with healthcare...

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

BriaCell Therapeutics Corp. (TSXV:BCT) (OTC:BCTXF) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it is finalizing the analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT™, with pembrolizumab (KEYTRUDA®; manufactur...

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key related findings as follows: ...

Exicure to Present at Spring Investor Summit 2019

Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CFO, David Snyder, will give a company presentation on Tuesday, April 2, 2019 at 9:30 am ET at the Spring Investor Summit. The presentation will be made at the Essex House in New York City. ...

Schrödinger Appoints Professor Brian Shoichet to Scientific Advisory Board

Schrödinger today announced the appointment of Professor of Chemistry Brian Shoichet, Ph.D., a widely published thought leader in the field of computational drug discovery, to its

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

The study did not achieve its primary end point of median overall survival in the whole population of 78 patients, however, superiority in median overall survival was found in the largest study subpopulation of 56 patients and in secondary end points including objective response in the whole population, strongly supporting the progressio...

RBMA Awards Scholarships to Promising New Radiology Leaders

Thanks to a successful 50th anniversary fundraiser, the Radiology Business Management Association has awarded a record number of Bob Luther Emerging Leader Travel Scholarships for 2019. FAIRFAX, Va. (PRWEB) March 26, 2019 For 2019, the Radiology Business Management Association has awarded a record three Bob Luther Emerging Leader Travel Scholarships—the most ever in a single year for the associ...

Jessica Wein Joins Lifecycle Biotechnologies As Marketing Strategist

Jessica Wein to lead and expand Lifecycle Biotechnologies marketing program FORT WORTH, Texas (PRWEB) March 26, 2019 Ms. Wein will be leading Lifecycle’s strategic marketing plans to achieve corporate objectives for the company’s products and services. In her position, Ms. Wein will also oversee Lifecycle’s social media channels, it’s educational blog on, maintain and fur...

How Israel Turned Decades Of Medical Data Into Digital Health Gold

Because of its small size and advanced technology, implementing a health record digitization project has been easier in Israel than it would likely be elsewhere.

Heartmate 3 LVAD Impresses in Final MOMENTUM 3 Data

Patients with advanced heart failure now have an option other than heart transplantation: a more forgiving heart pump that has now been studied out to 2 years in a large population. Medscape Medical News

LIV Fertility Center Celebrates New Parents After 15 Year Struggle with Infertility

Devastated to discover the medical complications that kept them from conceiving for 15 years, LIV Fertility Center new parents, Iqbal and Kim, are now celebrating the birth of their baby boy after successful fertility treatment in Mexico. LOS ANGELES (PRWEB) March 26, 2019 Devastated to discover the medical complications that kept them from conceiving for 15 years, LIV Fertility Center new parent...

CardioFocus gets CE mark for HeartLight X3 system to treat atrial fibrillation

HeartLight X3 system is a third generation technology developed by using advanced features from the HeartLight endoscopic ablation system. HeartLight endoscopic ablation system carries out pulmonary vein isolation The post CardioFocus gets CE mark for HeartLight X3 system to treat atrial fibrillation appeared first on Compelo Medical Devices - Latest industry news and analysis.

Endotoxemia-induced endothelial fibrosis inhibition improves hypotension, tachycardia, multiple organ dysfunction syndrome, cytokine response, oxidative stress, and survival

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis

Monday 25th March 2019

Medtronic Launches Medtech Innovation Accelerator in Shanghai

Early-Stage Business Accelerator to Empower Local MedTech Innovation and Enhance Medtronic China's Industry Leadership DUBLIN and SHANGHAI - March 25, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the Medtronic MedTech Innovation Accelerator in Pujiang International Science and Technology City at Minhang District, Shan...

Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence

Disagreement in risk groups for metastatic renal cancer

BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed the first tranche (“First Tranche”) of its previously-announced (March 20, 2019) non-brokered private placement of up to 20,000,000 common shares of the Company at ...

Ciming Boao International Hospital Fertility Center Begins First Trial Operations

BOAO, China, March 25, 2019 /PRNewswire/ -- Ciming Boao International Hospital and Fertility Center, a state-of-the-art 5,000sq meter facility has begun trial operations. Built on 16.5 acres of land located within the "Boao Lecheng Medical Tourism Pilot Zone," the hospital has received the support of the National Health Commission's Women and Children Department and will offer standard f...

Quick Search


News Quicklinks